Vitalea, Accium Collaborate to Cross-validate AMS Platform | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Bioanalytical contract services firms Vitalea Sciences and Accium BioSciences today announced an agreement to cross-validate each other's' accelerator mass spectrometry platform.

The companies said successful completion of the studies "will permit delivery of bioanalytical services supported by backup AMS instrumentation operating under a unified and validated framework."

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.